Soligenix

Monoclonal Antibody Therapies for Infectious Diseases

We entered into an ECC with Soligenix, Inc. (OTCQB: SNGX), a clinical-stage biopharmaceutical company that is working with us to develop and commercialize human monoclonal antibody therapies for the treatment of melioidosis, an often lethal disease that is endemic in Southeast Asia and Northern Australia.  It is also considered a high-priority biodefense threat with the potential for widespread dissemination through aerosol.
 
The lead therapeutic program of this ECC involves the development and commercialization of a human monoclonal antibody therapy to treat melioidosis, both in its naturally-occurring form and as a bio-threat.

Learn more about Soligenix
In the News